953 results on '"Herzog, Roland W"'
Search Results
2. SERCA2a overexpression improves muscle function in a canine Duchenne muscular dystrophy model
3. Chemical modification of AAV9 capsid with N-ethyl maleimide alters vector tissue tropism
4. B cell focused transient immune suppression protocol for efficient AAV readministration to the liver
5. A novel class of self-complementary AAV vectors with multiple advantages based on cceAAV lacking mutant ITR
6. TLR9-independent CD8+ T cell responses in hepatic AAV gene transfer through IL-1R1-MyD88 signaling
7. Cellular stress and coagulation factor production: when more is not necessarily better
8. Thrombotic microangiopathy following systemic AAV administration is dependent on anti-capsid antibodies
9. Factor IX administration in the skin primes inhibitor formation and sensitizes hemophilia B mice to systemic factor IX administration
10. A review of the rationale for gene therapy for hemophilia A with inhibitors: one-shot tolerance and treatment?
11. Plant cell-based drug delivery enhances affordability of biologics
12. Factor VIII trafficking to CD4+ T cells shapes its immunogenicity and requires several types of antigen-presenting cells
13. Ectopic clotting factor VIII expression and misfolding in hepatocytes as a cause for hepatocellular carcinoma
14. IL-15 blockade and rapamycin rescue multifactorial loss of factor VIII from AAV-transduced hepatocytes in hemophilia A mice
15. Assessment of the Gene Therapy Immune Response in the Canine Muscular Dystrophy Model
16. Immune complications and their management in inherited and acquired bleeding disorders
17. Redundancy in Innate Immune Pathways That Promote CD8 + T-Cell Responses in AAV1 Muscle Gene Transfer.
18. In memoriam: Kenneth I. Berns, MD, PhD (1938–2024)
19. Kenneth I. Berns, MD, PhD [1938–2024]
20. Thorough molecular configuration analysis of noncanonical AAV genomes in AAV vector preparations
21. Expansion, in vivo–ex vivo cycling, and genetic manipulation of primary human hepatocytes
22. Viral Vector Based Immunotherapy for Peanut Allergy.
23. Innate Immune Sensing of Adeno-Associated Virus Vectors.
24. Immune Responses to Viral Gene Therapy Vectors
25. Type I IFN Sensing by cDCs and CD4+ T Cell Help Are Both Requisite for Cross-Priming of AAV Capsid-Specific CD8+ T Cells
26. Comprehensive Comparison of AAV Purification Methods: Iodixanol Gradient Centrifugation vs. Immuno-Affinity Chromatography
27. Cas9-specific immune responses compromise local and systemic AAV CRISPR therapy in multiple dystrophic canine models
28. Plant cell-made protein antigens for induction of Oral tolerance
29. SLAMF6 in health and disease: Implications for therapeutic targeting
30. Update on clinical gene therapy for hemophilia
31. Thrombotic microangiopathy following systemic AAV administration is dependent on anti-capsid antibodies
32. The Nobel Prize awarded to pioneers of mRNA vaccines
33. Looking to the future of gene therapy for hemophilia A and B
34. Cellular stress and coagulation factor production: when more isn’t necessarily better
35. Potential role for oral tolerance in gene therapy
36. The Molecular Therapy family of journals continues to lead the field of gene and cell therapy
37. ASGCT 2023—Gene therapy is becoming medicine
38. Liver-specific in vivo base editing of Angptl3 via AAV delivery efficiently lowers blood lipid levels in mice
39. Plasmacytoid and conventional dendritic cells cooperate in crosspriming AAV capsid-specific CD8+ T cells
40. The Balance between CD8+ T Cell-Mediated Clearance of AAV-Encoded Antigen in the Liver and Tolerance Is Dependent on the Vector Dose
41. AAV-Mediated Gene Delivery to the Liver: Overview of Current Technologies and Methods
42. Distortion of journal impact factors in the era of paper mills
43. Supplementary Tables and Figures from SLAMF6 as a Regulator of Exhausted CD8+ T Cells in Cancer
44. Data from SLAMF6 as a Regulator of Exhausted CD8+ T Cells in Cancer
45. Supplementary Legends from SLAMF6 as a Regulator of Exhausted CD8+ T Cells in Cancer
46. Innovation and clinical progress in oral tolerance
47. Suppression of anti-drug antibody formation against coagulation factor VIII by oral delivery of anti-CD3 monoclonal antibody in hemophilia A mice
48. Two gene therapies for hemophilia available: Now what?
49. Adenoviral gene therapy for bladder cancer
50. Stable Gene Transfer and Expression of Human Blood Coagulation Factor IX after Intramuscular Injection of Recombinant Adeno-Associated Virus
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.